BioLineRx Ltd. 提交 6-K 文件，附有一份新闻稿
6-K - BioLineRx Ltd. (0001498403) (Filer)
BioLineRx Ltd. 于 2026 年 10 月 23 日提交 Form 6-K，称当日发布了一份新闻稿，并将其作为附件 1 随文件提交。该公司按《1934 年证券交易法》要求签署文件。
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
For the month of October 2026
Commission file number: 001-35223
BioLineRx Ltd.
(Translation of registrant’s name into English)
2 HaMa’ayan Street
Modi’in 7177871, Israel
(Address of Principal Executive Offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F ☒ Form 40-F ☐
On October 23, 2026, the registrant issued the press release which is filed as Exhibit 1 to this Report on Form 6-K.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| BioLineRx Ltd. | |||
| By: | /s/ Philip A. Serlin | ||
| Philip A. Serlin | |||
| Chief Executive Officer | |||
Dated: October 23, 2026
来源：SEC EDGAR · 本站存档